What is the address of Dr. An Deman nefroloog?

The registered office of Dr. An Deman nefroloog is located at Paillart 1 box B, 7880 Flobecq.

Is Dr. An Deman nefroloog still active?

Yes. According to the CBE (30 October 2026) Dr. An Deman nefroloog is active, legal situation “Normale toestand”, started on 8 October 2014.

Is Dr. An Deman nefroloog registered on Peppol?

Yes, Dr. An Deman nefroloog is registered on the Peppol network with ID 0208:0563779935.

What is the enterprise number of Dr. An Deman nefroloog?

The enterprise number of Dr. An Deman nefroloog is BE0563779935.

When was Dr. An Deman nefroloog founded?

Dr. An Deman nefroloog was founded on 8 October 2014.

Who are the directors of Dr. An Deman nefroloog?

According to the 2025 annual accounts, the directors of Dr. An Deman nefroloog are: An Deman.

Is Dr. An Deman nefroloog a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 8 October 2014; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. An Deman nefroloog make in 2025?

Dr. An Deman nefroloog posted a profit after taxes of € 240,982 in financial year 2025.

What is the revenue of Dr. An Deman nefroloog?

As a small company, Dr. An Deman nefroloog is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 332,196.

Dr. An Deman nefroloog (Private Limited) - Flobecq

Dossier Dr. An Deman nefroloog, printed on 30 October 2026 from databakkes.be/en/0563779935/dr-an-deman-nefroloog. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. An Deman nefroloog from Flobecq, company number BE0563779935, closed financial year 2025 with a result of € 240,982 after tax. For that financial year Dr. An Deman nefroloog recorded a gross margin of € 332,196 and equity of € 19,117. Compared with financial year 2024, the result moved from € 313,745 to € 240,982. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on January 14, 2026.

What it is worth Healthy

€ 19,117

▼ 33% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 240,982

▼ 23% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 217,841

▲ € 185,119 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 250,558 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 9,056

▼ 36% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 37,749

▲ 33% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 2,113

▼ 63% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,386

▼ 89% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 343,678 Gross margin 2022: € 343,678 First fiscal year in the series	€ 288,144 Gross margin 2023: € 288,144 ▼ 16% vs 2022 (€ 343,678) Unfavourable step	€ 418,248 Gross margin 2024: € 418,248 ▲ 45% vs 2023 (€ 288,144) Favourable step	€ 332,196 Gross margin 2025: € 332,196 ▼ 21% vs 2024 (€ 418,248) Unfavourable step	▼ 21%
Profit after taxes	€ 239,112 Profit after taxes 2022: € 239,112 First fiscal year in the series	€ 193,940 Profit after taxes 2023: € 193,940 ▼ 19% vs 2022 (€ 239,112) Unfavourable step	€ 313,745 Profit after taxes 2024: € 313,745 ▲ 62% vs 2023 (€ 193,940) Favourable step	€ 240,982 Profit after taxes 2025: € 240,982 ▼ 23% vs 2024 (€ 313,745) Unfavourable step	▼ 23%
Equity	€ 25,009 Equity 2022: € 25,009 First fiscal year in the series	€ 24,949 Equity 2023: € 24,949 Unchanged (€ 25,009) Unfavourable step	€ 28,694 Equity 2024: € 28,694 ▲ 15% vs 2023 (€ 24,949) Favourable step	€ 19,117 Equity 2025: € 19,117 ▼ 33% vs 2024 (€ 28,694) Unfavourable step	▼ 33%
Total debts	€ 247,802 Total debts 2022: € 247,802 First fiscal year in the series	€ 220,695 Total debts 2023: € 220,695 ▼ 11% vs 2022 (€ 247,802) Favourable step	€ 390,257 Total debts 2024: € 390,257 ▲ 77% vs 2023 (€ 220,695) Unfavourable step	€ 296,089 Total debts 2025: € 296,089 ▼ 24% vs 2024 (€ 390,257) Favourable step	▼ 24%
Cash	€ 174,628 Cash 2022: € 174,628 First fiscal year in the series	€ 109,944 Cash 2023: € 109,944 ▼ 37% vs 2022 (€ 174,628) Unfavourable step	€ 32,722 Cash 2024: € 32,722 ▼ 70% vs 2023 (€ 109,944) Unfavourable step	€ 217,841 Cash 2025: € 217,841 ▲ € 185,119 vs 2024 (€ 32,722) Favourable step	▲ € 185,119
Retained profit	€ 6,409 Retained profit 2022: € 6,409 First fiscal year in the series	€ 6,349 Retained profit 2023: € 6,349 ▼ 1% vs 2022 (€ 6,409) Unfavourable step	€ 10,094 Retained profit 2024: € 10,094 ▲ 59% vs 2023 (€ 6,349) Favourable step	€ 517 Retained profit 2025: € 517 ▼ 95% vs 2024 (€ 10,094) Unfavourable step	▼ 95%
Dividend	€ 240,000 Dividend 2022: € 240,000 First fiscal year in the series	€ 194,000 Dividend 2023: € 194,000 ▼ 19% vs 2022 (€ 240,000) Unchanged	€ 310,000 Dividend 2024: € 310,000 ▲ 60% vs 2023 (€ 194,000) Unchanged	€ 250,558 Dividend 2025: € 250,558 ▼ 19% vs 2024 (€ 310,000) Unchanged	▼ 19%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 28,398 Bank debt 2024: € 28,398 Unchanged (€ 0) Unfavourable step	€ 37,749 Bank debt 2025: € 37,749 ▲ 33% vs 2024 (€ 28,398) Unfavourable step	▲ 33%
Balance sheet total	€ 272,811 Balance sheet total 2022: € 272,811 First fiscal year in the series	€ 245,645 Balance sheet total 2023: € 245,645 ▼ 10% vs 2022 (€ 272,811) Unchanged	€ 418,951 Balance sheet total 2024: € 418,951 ▲ 71% vs 2023 (€ 245,645) Unchanged	€ 315,206 Balance sheet total 2025: € 315,206 ▼ 25% vs 2024 (€ 418,951) Unchanged	▼ 25%

Key figures of Dr. An Deman nefroloog, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to Dr. An Deman nefroloog?

What happened at Dr. An Deman nefroloog in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jan 14, 2026 New annual accounts for financial year 2025: profit of € 240,982 (▼ 23% vs 2024). Source: NBB ↗
Oct 8, 2014 New establishment in Gent. KBO
Oct 8, 2014 Start of the company according to the CBE. KBO

In short

From € 239,112 profit in 2022 to € 240,982 profit in 2025.

Paid € 325,768 in corporate taxes since 2022.

Best year ever: 2024, with € 313,745 profit.

Paid out € 994,558 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

An Deman

Dr. An Deman nefroloog

Behind Dr. An Deman nefroloog is An Deman.

Directors

According to the 2025 annual accounts

An Deman

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Paillart 1 box B

7880 Flobecq

2.235.771.311

Kortrijksesteenweg 1026

9000 Gent

Active since 8 October 2014

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

Dr. Olivier Fabré orthopedisch chirurg

€ 388,039 gross margin · 2025

BRIMBERT CONSTRUCT

€ 763,729 revenue · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0563.779.935
VAT number: BE 0563.779.935
Registered office: Paillart 1 bus B, 7880 Flobecq
Names & denominations: Dr. An Deman nefroloog
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 8 October 2014
Peppol: Active · Active since 9 Oct 2025

View on CBE Public ↗ Annual accounts (NBB) ↗